News
Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the synergistic effect of these modern medications.
Variability of COPD Symptoms During the Day and Impact on Patients' Morning Routine – Survey Results
Chronic obstructive pulmonary disease (COPD) is viewed, unlike bronchial asthma, as a condition…
Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage
The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the…
New Strategies in the Treatment of Schizophrenia
Schizophrenia was primarily associated with dopamine dysfunction. Previous and current treatments…
Is it safe to start dabigatran in the first days after ischemic stroke?
For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial,…
Is the combination of tiotropium/olodaterol proven more effective in reducing the risk of clinically significant worsening of COPD compared to monotherapy?
Given the heterogeneity of chronic obstructive pulmonary disease (COPD), the use of a composite…
Impact of Chronic Urticaria on Patients' Quality of Life and Society
An international team of dermatologists has mapped out the impact of chronic urticaria on various…
Perioperative substitution therapy in patients with vWD must be tailored
Even in cases of von Willebrand disease (vWD), available data supports the need for individualized…
Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease
A study published last year in the Journal of Thrombosis and Haemostasis presents the results of…
The Position of Lurasidone in Schizophrenia Therapy − Current Conclusions and Consensus of the Expert Panel
Lurasidone is an antipsychotic belonging to the group of serotonin and dopamine antagonists (SDA)…